Merck and Moderna's Personalized Melanoma Vaccine Keeps 82% Cancer-Free at Two Years

Merck and Moderna released full Phase III results for intismeran autogene, a personalized mRNA vaccine for high-risk melanoma. Combined with Keytruda, it cut the risk of recurrence or death by 42% and distant metastasis or death by 38%; 82.2% of vaccinated patients remained cancer-free at two years versus 70% on Keytruda alone.

• Trial enrolled 1,137 patients with stage 2B–4 melanoma
• Recurrence or death risk cut by 42% at two years
• 82.2% cancer-free versus 70% on Keytruda alone
• Vaccine targets up to 34 tumor neoantigens